Israel's Betalin Therapeutics plans IPO to fund diabetes trialsThe company, which is funded by private investors, is looking to raise about $40 million in an IPO in New York or London by the end of next year.A blood glucose test is done to check sugar levels in a Type 2 Diabetes patient(photo credit: DARRYL LEJA/NIH/FLICKR)
